Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies-Reference-Cited by-同舟云学术

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies

Published:2014-03-14 Issue:5 Volume:49 Page:941-953
ISSN:0944-1174
Container-title:Journal of Gastroenterology
language:en
Short-container-title:J Gastroenterol

Author:

Izumi Namiki,Hayashi Norio,Kumada Hiromitsu,Okanoue Takeshi,Tsubouchi Hirohito,Yatsuhashi Hiroshi,Kato Mai,Ki Rito,Komada Yuji,Seto Chiharu,Goto Shoichiro

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology

Link

http://link.springer.com/content/pdf/10.1007/s00535-014-0949-8.pdf

Reference32 articles.

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17:107–15.

2. Chung H, Ueda T, Kudo M. Changing trends in hepatitis C infection over the past 50 years in Japan. Intervirology. 2010;53:39–43.

3. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(Suppl 19):102–7.

4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55:245–64.

5. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology. 2010;78(Suppl 1):78–86.

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment progress and expansion in Japan: From interferon to direct-acting antiviral;Global Health & Medicine;2021-10-31

2. Trends in hepatitis C virus‐associated mortality rates in Japan, 1998–2017;Journal of Gastroenterology and Hepatology;2021-05

3. Variations in IL-22, IL-27 and IL-35 serum levels in untreated and treated hepatitis C patients;European Cytokine Network;2020-12

4. Hepatitis C virus (HCV) : Development of anti-HCV agents and anti-HCV therapy;Okayama Igakkai Zasshi (Journal of Okayama Medical Association);2020-12-01

5. Eltrombopag enables initiation and completion of pegylated interferon/ribavirin therapy in Japanese HCV‑infected patients with chronic liver disease and thrombocytopenia;Experimental and Therapeutic Medicine;2019-05-24